{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "CLOSED", "regularMarketChangePercent": -3.2570415, "regularMarketPrice": 2.7475, "exchange": "IOB", "shortName": "INNATE PHARMA SA INNATE PHARMA ", "longName": "Innate Pharma S.A.", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683909467, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.74, "sharesOutstanding": 80203400, "bookValue": 0.675, "fiftyDayAverage": 2.8297994, "fiftyDayAverageChange": -0.08229947, "fiftyDayAverageChangePercent": -0.029083146, "twoHundredDayAverage": 2.657681, "twoHundredDayAverageChange": 0.089818954, "twoHundredDayAverageChangePercent": 0.033795986, "marketCap": 220358832, "priceToBook": 4.07037, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1310022000000, "priceHint": 4, "regularMarketChange": -0.09249997, "regularMarketDayHigh": 2.73, "regularMarketDayRange": "2.73 - 2.73", "regularMarketDayLow": 2.73, "regularMarketVolume": 1499, "regularMarketPreviousClose": 2.84, "bid": 2.68, "ask": 2.815, "bidSize": 0, "askSize": 0, "fullExchangeName": "IOB", "financialCurrency": "EUR", "regularMarketOpen": 2.73, "averageDailyVolume3Month": 2666, "averageDailyVolume10Day": 1889, "fiftyTwoWeekLowChange": 0.7528199, "fiftyTwoWeekLowChangePercent": 0.37741387, "fiftyTwoWeekRange": "1.99468 - 3.78", "fiftyTwoWeekHighChange": -1.0325, "fiftyTwoWeekHighChangePercent": -0.27314815, "fiftyTwoWeekLow": 1.99468, "fiftyTwoWeekHigh": 3.78, "symbol": "0EVI.IL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.", "fullTimeEmployees": 211, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herve  Brailly", "age": 61, "title": "Co-Founder & Chairman of Supervisory Board", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mondher  Mahjoubi M.D.", "age": 64, "title": "Chairman of Exec. Board & CEO", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 813442, "fmt": "813.44k", "longFmt": "813,442"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 49, "title": "Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 372783, "fmt": "372.78k", "longFmt": "372,783"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 58, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2014, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 58, "title": "Founder, Sr. VP & Chief Scientific Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 62, "title": "Founder", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 47, "title": "Sr. VP & CFO", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Odile  Belzunce", "age": 42, "title": "VP of Compliance & Operations", "yearBorn": 1980, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}